Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.46 |
| ▸ | HEXA | P06865 | 1/20 | 0.45 |
| ▸ | HEXB | P07686 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 9/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302563 | 0.94 | HEXA (0.47) | TRPV1FTOHEXAHEXBCYP2D6 | |
| SCHEMBL3294784 | 0.87 | FTO (0.54) | FTOHEXAHEXBCYP2D6PLK1 | |
| SCHEMBL3296718 | 0.84 | HDAC3 (0.50) | FTOHEXAHEXBCYP2D6ALDH1A1 | |
| SCHEMBL3299473 | 0.84 | FTO (0.51) | FTOHEXAHEXBCYP2D6ALDH1A1 | |
| SCHEMBL3297122 | 0.84 | HDAC3 (0.52) | FTOHEXAHEXBCYP2D6ALDH1A1 | |
| SCHEMBL3300095 | 0.83 | FTO (0.49) | FTOHEXAHEXBCYP2D6PABPC1 | |
| SCHEMBL3302098 | 0.81 | HEXA (0.47) | FTOHEXAHEXBCYP2D6ALDH1A1 | |
| SCHEMBL14528306 | 0.81 | HEXA (0.47) | FTOHEXAHEXBCYP2D6ALDH1A1 | |
| SCHEMBL3300198 | 0.81 | HEXA (0.53) | FTOHEXAHEXBCYP2D6ALDH1A1 | |
| SCHEMBL13297981 | 0.81 | HEXA (0.48) | FTOHEXAHEXBCYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741337-B2 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | UNIBIOSCREEN S.A. (BE) | 2010-06-22 | — | — | US | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1787985-A1 | Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom | Unibioscreen S.A. (BE) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TRPV1 1912/4885FTO 595/4885HEXA 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.